Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 80,000 shares at $42.73 ($3.4M) on 2025-07-02, disclosed to the SEC on 2025-07-03.
Scheduled sale ($3.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.50 | 18,300 | $778K | 22.8% |
| 2 | $42.51 | 18,400 | $782K | 22.9% |
| 3 | $42.88 | 1,700 | $73K | 2.1% |
| 4 | $42.89 | 1,600 | $69K | 2.0% |
| 5 | $42.73 | 20,000 | $855K | 25.1% |
| 6 | $42.73 | 20,000 |
| $855K |
| 25.1% |
| Total | $42.63 avg | 80,000 | $3.4M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |